UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	FORM 10-Q	
(Mark One) ☑ QUARTERLY REPORT UNDER SECTI	ON 13 OR 15(d) OF THE SECU	URITIES EXCHANGE ACT OF 1934
For th	e quarterly period ended: June 30, 202	22
	OR	
☐ TRANSITION REPORT PURSUANT TO 1934	O SECTION 13 OR 15(d) OF T	HE SECURITIES EXCHANGE ACT OF
For the transition	n period from to	
C	ommission File Number 000-56075	
4Fro	ont Ventures Con	~ D.
	ame of registrant as specified in its char	-
British Columbia (State or other jurisdiction of incorporation or organization)		83-4168417 (IRS Employer Identification No.)
	5060 N. 40th Street	
(Add	Suite 120 Phoenix, Arizona 85018 ress of principal executive offices and zip code)	
Registrant's teler	ohone number, including area code: (60)2) 633-3067
	egistered pursuant to Section 12(b) of t	
	Trading	Name of Each Exchange
Title of Each Class Class A Subordinate Voting Shares, no par value	Symbol(s) FFNTF	on Which Registered OTCQX
Country to the state of the sta	FFNT	CSE
Indicate by check mark whether the registrant (1) has filed during the preceding 12 months (or for such shorter perior requirements for the past 90 days. Yes ⊠ No □		
Indicate by check mark whether the registrant has submitt Regulation S-T (Section 232.405 of this chapter) during the		

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an

files). Yes ⊠ No □

emerging growth company company in Rule 12b-2 o	y. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting f the Exchange Act:	g company," and "emerging gro	wth					
Large accelerated filer		Accelerated filer						
Non-accelerated filer		Smaller reporting company	\boxtimes					
		Emerging growth company	\boxtimes					
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.								
Indicate by check mark wh	Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes □ No ☒							
As of August 15, 2022, the	registrant had 636,636,686 Class A subordinate voting shares outstanding.							

4Front Ventures Corp.

FORM 10-Q FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022

TABLE OF CONTENTS

PART I.	FINANCIAL INFORMATION	Page
Item 1.	Consolidated Financial Statements (unaudited)	
	Condensed Consolidated Interim Balance Sheets	1
	Condensed Consolidated Interim Statements of Operations	2
	Condensed Consolidated Interim Statements of Changes in Stockholders' Equity	3
	Condensed Consolidated Interim Statements of Cash Flows	5
	Notes to Condensed Consolidated Interim Financial Statements (unaudited)	6
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	29
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	38
Item 4.	Controls and Procedures	38
PART II.	OTHER INFORMATION	
Item 1.	<u>Legal Proceedings</u>	40
Item 1A.	Risk Factors	40
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	41
Item 3.	Defaults Upon Senior Securities	41
Item 4.	Mine Safety Disclosures	41
Item 5.	Other Information	41
Item 6.	<u>Exhibits</u>	42
Signatures		43

i

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

4FRONT VENTURES CORP.

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (unaudited)

As of June 30, 2022 and December 31, 2021

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

	June 30, 2022	Dece	mber 31, 2021
ASSETS			
Current assets:			
Cash	\$ 6,032	\$	22,581
Accounts receivable, net	5,844		1,946
Other receivables	33		289
Current portion of lease receivables	3,405		3,630
Inventory	28,837		20,087
Current portion of notes receivable	2.074		109
Prepaid expenses	2,974		2,232
Total current assets	47,125		50,874
Property, plant, and equipment, net	58,967		42,633
Lease receivables	6,541		6,748
Intangible assets, net	54,239		26,246
Goodwill	42,037		23,155
Right-of-use assets	106,406		100,519
Deposits	5,142		5,364
TOTAL ASSETS	\$ 320,457	\$	255,539
LIABILITIES AND SHAREHOLDERS' EQUITY			
LIABILITIES			
Current liabilities:		•	2.424
Accounts payable	\$ 6,391	\$	2,131
Accrued expenses and other current liabilities	13,031		9,411
Taxes payable Derivative liability	29,651		23,968
Current portion of contract liabilities	428		3,502
Current portion of convertible notes	1,535		2,784
Current portion of convertible notes Current portion of lease liability	4,121		3,629
Current portion of notes payable and accrued interest	8,235		3,41
Total current liabilities	63,392	_	48,838
Convertible notes	15,205		14,64
Notes payable and accrued interest from related party Long term notes payable	49,366 10,128		48,260
Long term accounts payable	1,200		1,709 1,200
Contract liabilities	2,000		1,200
Contingent consideration payable	2,000		2,393
Construction finance liability	16,000		2,37.
Deferred tax liability	6,884		7,849
Lease liability	101,380		93,111
TOTAL LIABILITIES	265,555	_	218,007
SHAREHOLDERS' EQUITY			210,00
Equity attributable to 4Front Ventures Corp.	302,502		274,120
Additional paid-in capital	53,625		52,197
Deficit	(301,307)		(288,857
Non-controlling interest	(301,307)		72
TOTAL SHAREHOLDERS' EQUITY	54,902		37,532
•		Φ.	
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 320,457	\$	255,539

See accompanying notes to financial statements.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS (unaudited)

For the Three and Six Months Ended June $30,\,2022$ and 2021

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

	Three Months Ended June 30, 2022 2021			Six Months E 2022	nded June 30, 2021			
REVENUE	<u> </u>		, <u> </u>					
Revenue from sale of goods	\$	25,488	\$	24,452	\$	48,571	\$	44,532
Real estate income		2,951		2,669		5,916		5,559
Total revenues		28,439		27,121		54,487		50,091
Cost of goods sold		(16,123)		(10,816)		(28,717)		(19,941)
Gross profit		12,316		16,305		25,770		30,150
OPERATING EXPENSES								
Selling and marketing expenses		6,327		6,714		11,493		11,871
General and administrative expenses		6,566		5,083		14,210		10,248
Depreciation and amortization		1,123		861		1,970		1,635
Transaction and restructuring related expenses		2,009		—		2,009		_
Equity based compensation		390		2,979		1,428		5,375
Total operating expenses		16,415		15,637		31,110		29,129
(Loss) Income from operations	,	(4,099)		668	,	(5,340)		1,021
Other income (expense)								
Interest income		_		8		2		11
Interest expense		(3,418)		(2,901)		(6,038)		(5,362)
Amortization of loan discount upon conversion of debt to equity		—		—				(2,915)
Change in fair value of derivative liability		1,774		(311)		3,074		(2,843)
Change in contingent consideration payable		2,393		_		2,393		
Loss on lease termination		_		(331)		_		(1,210)
Other		(154)				(51)		
Total other income (expense), net		595		(3,535)		(620)		(12,319)
Net loss before income taxes		(3,504)		(2,867)		(5,960)		(11,298)
Income tax expense		(3,042)		(3,351)		(6,480)		(6,004)
Net loss		(6,546)		(6,218)		(12,440)		(17,302)
Net income attributable to non-controlling interest		5		5		10		10
Net loss attributable to shareholders	\$	(6,551)	\$	(6,223)	\$	(12,450)	\$	(17,312)
Basic and diluted loss per share	\$	(0.01)	\$	(0.01)	\$	(0.02)	\$	(0.03)
Weighted average number of shares outstanding, basic and diluted	630	6,653,975	58′	7,218,794	62	8,175,765	57	3,108,183

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited)

For the Six Months Ended June 30, 2022 and 2021

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

	Share Ca	pital							
	Shares	Amount	Additional Paid-In Capital	Deficit	Vent Sha	tal 4Front tures Corp. reholders' Equity	Conti	on- rolling erest	Total reholders' Equity
Balance, December 31, 2021	594,181,604	\$274,120	\$ 52,197	\$(288,857)	\$	37,460	\$	72	\$ 37,532
Shares issued for NECC pursuant to									
acquisition	28,571,428	18,200				18,200			18,200
Share-based compensation	_	_	1,038	_		1,038			1,038
Conversion of notes to equity	6,235,512	3,122				3,122			3,122
Shares issued with exercise of warrants	88,659	50		_		50		—	50
Net loss	_	_		(5,899)		(5,899)		5	(5,894)
Balance, March 31, 2022	629,077,203	\$295,492	\$ 53,235	\$(294,756)	\$	53,971	\$	77	\$ 54,048
Shares issued for Island pursuant to acquisition	8,783,716	6,245	_	_		6,245		_	6,245
Warrants issued for Island pursuant to									
acquisition	_	732	_	_		732		—	732
Share-based compensation	_	_	390	_		390		_	390
Shares issued with exercise of stock options	51,975	33	_	_		33		_	33
Net loss				(6,551)		(6,551)		5	(6,546)
Balance, June 30, 2022	637,912,894	\$302,502	\$ 53,625	\$(301,307)	\$	54,820	\$	82	\$ 54,902

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited)

For the Six Months Ended June 30, 2022 and 2021

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

		Share Ca	pital							
		Shares	Amount	Additional Paid-In Capital	Deficit	Ven	tal 4Front tures Corp. areholders' Equity	Con	Non- trolling terest	Total reholders' Equity
Ba	lance, December 31, 2020	538,851,252	\$250,583	\$ 42,116	\$(250,548)	\$	42,151	\$	52	\$ 42,203
	Shares issued for Pure Ratios earnout	473,491	161				161			161
	Share-based compensation	_	_	2,396	_		2,396		_	2,396
	Conversion of notes to equity	24,366,003	6,253	_	_		6,253		_	6,253
	Shares issued with exercise of stock options	1,358,116	871	_	_		871		_	871
	Shares issued with exercise of warrants	2,422,363	1,563	_	_		1,563		_	1,563
	Return of treasury shares	(8,320)	—		_		_			_
	Net loss	_	_		(11,089)		(11,089)		5	(11,084)
Ba	lance, March 31, 2021	567,462,905	\$259,431	\$ 44,512	\$(261,637)	\$	42,306	\$	57	\$ 42,363
	Shares issued for Om of Medicine earnout	535,018	722	_	_		722		_	722
	Share-based compensation	_	_	2,979	_		2,979		_	2,979
	Conversion of notes to equity	24,676,794	11,466				11,466		_	11,466
	Shares issued with exercise of stock options	652,940	443	_	_		443		_	443
	Shares issued with exercise of warrants	570,864	1,813				1,813		_	1,813
	Net loss				(6,223)		(6,223)		5	(6,218)
Ba	lance, June 30, 2021	593,898,521	\$273,875	\$ 47,491	\$(267,860)	\$	53,506	\$	62	\$ 53,568

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited)

For the Six Months Ended June 30, 2022 and 2021

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

	Six Months Ended Jun	
ALAW BY ANY ADD A CARD LINES A CONTRACTOR		2021
CASH FLOWS FROM OPERATING ACTIVITIES	0 (10 110)	
Net loss	\$ (12,440)	\$ (17,302)
Adjustments to reconcile net loss to net cash used by operating activities	4.600	
Depreciation and amortization	4,689	2,166
Equity based compensation	1,428	5,375
Change in fair value of derivative liability	(3,074)	2,843
Change in fair value of contingent consideration	(2,393)	_
Amortization of right-of-use assets		1,765
Accretion of lease liability	2,803	(478)
Write-off of fixed asset from terminated lease		1,210
Accretion of contingent consideration	_	228
Accretion of convertible debenture and interest	564	850
Accrued interest on notes payable	3,614	3,884
Interest accrued - lease receivable	432	349
Deferred taxes	(965)	632
Amortization of loan discount upon conversion of debt to equity	_	2,915
Changes in operating assets and liabilities	2,458	(170)
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES	(2,884)	4,267
CASH FLOWS FROM INVESTING ACTIVITIES		
Payment for NECC business combination, net of cash acquired	(24,998)	
Cash acquired as part of Island business combination	458	_
Notes receivable repayments	109	405
Sale of dispensaries and interests in cannabis licenses	_	1,093
Purchases of property and equipment	(2,249)	(12,234)
NET CASH USED IN INVESTING ACTIVITIES	(26,680)	(10,736)
CASH FLOWS FROM FINANCING ACTIVITIES		
Payment of contingent consideration	(412)	(1,204)
Proceeds from issuance of construction financing liability	16,000	_
Proceeds from the exercise of warrants	50	1,664
Proceeds from the exercise of stock options	33	1,314
Repayment of notes payable	(2,656)	(2,674)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	13,015	(900)
NET DECREASE IN CASH	(16,549)	(7,369)
CASH, BEGINNING OF QUARTER	22,581	18,932
CASH, END OF QUARTER	\$ 6,032	\$ 11,563
CASH, END OF QUARTER	\$ 0,032	φ 11,303

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Note 1: NATURE OF OPERATIONS

4Front Ventures Corp. ("4Front" or the "Company") exists pursuant to the provisions of the British Columbia Corporations Act. On July 31, 2019, 4Front Holdings LLC ("Holdings") completed a Reverse Takeover Transaction ("RTO") with Cannex Capital Holdings Inc. ("Cannex") whereby Holdings acquired Cannex and the shareholders of Holdings became the controlling shareholders of the Company. Following the RTO, the Company's SVS are listed on the Canadian Securities Exchange ("CSE") under the ticker "FFNT" and are quoted on the OTC (OTCQX: FFNTF).

The Company has two primary operating segments: THC Cannabis and CBD Wellness. With regard to its THC Cannabis segment, as of June 30, 2022, the Company operates six dispensaries in Massachusetts, Illinois, and Michigan, primarily under the "MISSION" brand name. As of June 30, 2022, the Company operates three production facilities in Massachusetts, Illinois and California and produces the majority of products that are sold at its own Massachusetts and Illinois dispensaries. Also, as part of its THC Cannabis segment, the Company leases real estate and sells equipment, supplies, and intellectual property to cannabis producers in the state of Washington.

While marijuana is legal under the laws of several U.S. states (with varying restrictions), the United States Federal Controlled Substances Act classifies all "marijuana" as a Schedule 1 drug, whether for medical or recreational use. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision.

The Company's CBD Wellness segment is focused upon its ownership and operation of its wholly owned subsidiary, Pure Ratios Holdings, Inc. ("Pure Ratios"), a CBD-focused wellness company in California, that sells non-THC hemp derived products throughout the United States.

On January 28, 2022, the Company entered into an agreement and plan of merger (the "NECC Merger Agreement") with New England Cannabis Corporation, Inc., a Massachusetts Corporation ("NECC") and a wholly owned subsidiary of the Company entered into an amended membership interest purchase agreement (the "Everett Purchase Agreement," and together with the NECC Merger Agreement, the "NECC Merger Agreements") with Kenneth Stevens to purchase all of the membership interests of 29 Everett, LLC ("29 Everett"), a Massachusetts limited liability company. See Note 7 for further details on the NECC Merger Agreements and corresponding transactions under such agreements.

On March 30, 2022, the Company entered into an agreement and plan of merger (the "Island Merger Agreement") by and among the Company, Island Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Island Merger Sub"); Island Global Holdings, Inc., a California corporation ("Island"); and Navy Capital SR LLC, a Delaware limited liability company ("Navy", and together with the Company, Island Merger Sub, and Island, the "Island Parties"). In April 2022, pursuant to the terms and conditions of the Merger Agreement, Island Merger Sub merged with and into Island, with Island surviving the merger and continuing its corporate existence as a wholly owned subsidiary of the Company (the "Island Merger"). See Note 7 for further details on the Island Merger Agreements and corresponding transactions under such agreements.

Management continues to evaluate the impact of the COVID-19 pandemic on the Company's industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company's financial position and results of its operations, the specific impact is not readily determinable as of the date of these consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The corporate office address of the Company is 5060 North 40th Street, Suite 120, Phoenix, Arizona, and the Company's registered office is 550 Burrard Street, Suite 2900, Vancouver, British Columbia.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Note 2: BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission (the "SEC"). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to such rules and regulations.

In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company's audited financial statements and notes thereto for the year ended December 31, 2021, included in the Company's Annual Report on Form 10-K, filed April 18, 2022, with the U.S. Securities and Exchange Commission, as well as the Company's Amendment to the Annual Report on Form 10-K, filed April 21, 2022, and on the System for Electronic Document Analysis and Retrieval in Canada (or SEDAR). The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

There have been no changes to the Company's significant accounting policies as described in Note 2 of the Company's 2021 Annual Report on Form 10-K. The Company's accounting policies have remained consistent with those disclosed in the latest annual consolidated financial statements except for the additional policy noted below.

Principles of consolidation

The accompanying condensed consolidated interim financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. The financial results of NECC are included in the condensed consolidated financial statements beginning on January 28, 2022, the merger closing date. The financial results of Island are included in the condensed consolidated financial statements beginning on April 25, 2022, the merger closing date.

The financial statements of the subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies.

Note 3: SIGNIFICANT ACCOUNTING POLICIES

(a) Critical accounting estimates and judgments

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of the Company's condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. The significant judgments made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those described in the latest annual consolidated financial statements, except for additional accounting policies identified during the interim period noted below.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Contract Assets and Liabilities

To the extent that the customer has paid consideration before transferring goods or services to the customer, a contract liability is recorded on the consolidated balance sheet as current portion of contract liabilities for contract liabilities due within twelve months or contract liabilities for contract liabilities due after twelve months. When the Company has an unconditional right to payment, a receivable is recorded on the consolidated balance sheet as current portion of contract assets for contract assets due after twelve months. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date are classified as current portion of contract liabilities in the accompanying condensed balance sheets. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as contract liabilities. The accompanying condensed balance sheets reflect a contract liability for the amount of revenue to be recognized in the future as and when the Company satisfies its remaining performance obligations. As of June 30, 2022, in connection with the Island Merger, the Company had recognized \$3,535 of contract liabilities, \$1,535 of which were recorded as current liabilities and \$2,000 were recorded as long term liabilities. See Note 7 for further discussion on the Island Merger.

We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations. We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary.

(b) Recent Accounting Pronouncements

Recently Adopted

- i. In August 2020, the FASB issued ASU 2020-06, "Debt Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity's Own Equity (Subtopic 815-40)". ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity's own equity. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Adoption of this standard did not materially impact the Company's consolidated financial position, results of operations or cash flows.
- ii. In May 2021, the FASB issued ASU 2021-04, "Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (Subtopic 815-40)". ASU 2021-04 clarifies and reduces diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Adoption of this standard did not materially impact the Company's consolidated financial position, results of operations or cash flows.
- iii. In October 2021, the FASB issued ASU 2021-08, "Business Combinations—Accounting for Contract Assets and Contract Liabilities (Topic 805)". The amendments in this update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination by requiring that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. As a result of the amendments made by the ASU, it is expected than an acquirer will generally recognize and measure acquired contract assets and contract liabilities in a manner consistent with how the acquiree recognized and measured them in its pre-acquisition financial statements. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. An entity that early adopts in an interim period should apply the amendments (i) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (ii) prospectively to all business combinations that occur on or after the date of initial application. The Company has elected to early adopt this standard as of January 1, 2022. The adoption of the standard had an impact on the valuation of Island deferred revenue contracts upon the acquisition date. The Company recognized the contract liabilities acquired consistent with the previous accounting treatment at the acquired entity. This standard did not have an impact on the NECC acquisition entered into on January 28, 2022.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Accounting Pronouncements Not Yet Adopted

i. In June 2022, the FASB issued ASU 2022-03, "Fair Value Measurements—Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (Topic 820)". ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. It also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. For public business entities, the ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted and the amendments in the ASU should be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. The Company is currently assessing the impact of adopting ASU 2022-03 on the consolidated financial statements.

Note 4: INVENTORY

The Company's inventories include the following as of June 30, 2022 and December 31, 2021:

	June 30, 2022	December 31, 2021
Raw materials - unharvested cannabis	\$ 2,849	\$ 2,164
Raw materials - harvested and purchased cannabis	10,824	3,045
Packaging and other non-finished goods	2,986	1,734
Work in process - manufactured and purchased extracts	4,825	4,771
Finished goods	7,353	8,373
Total	\$ 28,837	\$ 20,087

Note 5: PROPERTY, PLANT, AND EQUIPMENT

Property, plant and equipment and related depreciation are summarized in the table below:

	June 30, 2022	Dec	cember 31, 2021
Land	\$ 775	\$	
Buildings & improvements	13,896		1,483
Construction in process	702		63
Furniture, equipment & other	17,974		13,425
Leasehold improvements	36,878		35,538
Total	\$ 70,225	\$	50,509
Less: accumulated depreciation	(11,258)		(7,876)
Total property, plant, and equipment, net	\$ 58,967	\$	42,633

On January 28, 2022, in conjunction with a business combination with NECC, the Company acquired property, plant, and equipment totaling \$15,238 (Note 7). The Company subsequently sold the property, plant, and equipment to a third-party and leased back the equipment from the third-party. As discussed in Note 9, the Company recognized this fact pattern as a failed sale-leaseback transaction, whereby the Company recognized the fixed assets on the balance sheet of NECC and established a construction finance liability for rental payments made as part of the lease agreement.

On April 25, 2022, in conjunction with a business combination with Island, the Company acquired property and equipment totaling \$2,214. (Note 7).

Approximately \$33,000 of property and equipment is secured by LI Lending as collateral on the LI Lending note (Note 9). There were no significant contractual commitments for future capital expenditures as of June 30, 2022 and December 31, 2021.

Depreciation of property, plant, and equipment is computed using the straight-line method over the asset's estimated useful life. The Company does not depreciate land, which has an indefinite useful life. Depreciation expense for the six months ended June 30, 2022 and 2021 was \$3,382 and \$1,138, respectively, of which \$2,719 and \$725, respectively, is included in cost of goods sold. Depreciation expense for the three months ended June 30, 2022 and 2021 was \$2,217 and \$675, respectively, of which \$1,771 and \$400, respectively, is included in cost of goods sold.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Note 6: INTANGIBLE ASSETS AND GOODWILL

Intangible Assets

Intangible assets are recorded at cost less accumulated amortization and impairment losses. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is recognized on a straight-line basis over their estimated useful lives. The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively.

Intangible assets and related amortization are summarized in the table below:

	Licenses	istomer tionships	ompetition eements	Kn	ow-How	denames and demarks	Total
Balance, December 31, 2020	\$20,146	\$ 1,668	\$ 43	\$	6,933	\$ 	\$28,790
Amortization expense		(580)	 (43)		(1,921)	 	(2,544)
Balance, December 31, 2021	\$20,146	\$ 1,088	\$ _	\$	5,012	\$ _	\$26,246
NECC merger and 29 Everett acquisition (Note 7)	18,000	_	_		_	_	18,000
Island merger (Note 7)	8,700	_	—		_	2,600	11,300
Amortization expense		(290)			(970)	(47)	(1,307)
Balance, June 30, 2022	\$46,846	\$ 798	\$ _	\$	4,042	\$ 2,553	\$54,239

Goodwill

Balance, December 31, 2020	\$23,155
Balance, December 31, 2021	\$23,155
NECC merger and 29 Everett acquisition (Note 7)	12,547
Island merger (Note 7)	6,335
Balance, June 30, 2022	\$42,037

Impairment of Intangible Assets and Goodwill

On an annual basis, the Company assesses the Company's reporting units ("RUs") for indicators of impairment or when facts or circumstances suggest that it is more likely than not that the carrying amount may exceed fair value. For the purpose of impairment testing, goodwill is allocated to the Company's RUs to which it relates.

Goodwill was not tested for impairment during the six months ended June 30, 2022.

Six Months Ended June 30, 2022

On January 28, 2022, the Company entered into the NECC Merger Agreements with NECC and 29 Everett for total consideration of \$45,200. As part of the purchase price allocation of the acquisition and merger, the Company recognized \$18,000 of acquired licenses and \$12,547 of goodwill based on the consideration transferred and fair value of net assets acquired.

On April 25, 2022, the Company entered into the Island Merger Agreement with Island for total consideration of \$16,977. As part of the purchase price allocation of the acquisition and merger, the Company recognized \$8,700 of acquired licenses, \$2,600 of trade names and trademarks and \$6,335 of goodwill based on the consideration transferred and fair value of net assets acquired.

For further details on the acquisitions and purchase price allocations, see Note 7.

Year Ended December 31, 2021

In 2021, management assessed indicators of impairment and concluded the below for the respective RUs:

Retail, Production and Ancillary Cannabis Reporting Units

Management did not identify any significant negative triggering events that would suggest it is more likely than not that impairment exists. Therefore, further analysis was not required for these RUs.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Pure Ratios RU

As of June 30, 2022 and December 31, 2021, the accumulated impairment is \$13,400, which is due to goodwill impairment of the entire outstanding balance of goodwill on the Pure Ratios segment for the year ended December 31, 2020. As a result, the segment does not have a balance of goodwill or intangible assets remaining as of December 31, 2021.

Note 7: ACQUISITIONS AND BUSINESS COMBINATIONS

NECC Merger Agreement

On January 28, 2022, the Company entered into the merger agreement (the "NECC Merger") with NECC, Kenneth V. Stevens ("Mr. Stevens"), who is the sole owner of all of the issued and outstanding capital stock of NECC, and 4Front NECC Acquisition Co., a Massachusetts corporation (the "NECC Merger Sub"). At the effective time of the merger, the Company (i) paid Mr. Stevens cash in the amount of \$9,000,000, and (ii) issued Mr. Stevens 28,571,428 Class A Subordinate Voting shares of the Company (the "SVS").

In connection with the consummation of the NECC Merger on January 28, 2022, Mission Partners RE, LLC, a Delaware limited liability company wholly owned by the Company ("Mission Partners RE"), and Mr. Stevens entered into the first amendment to that certain membership interest purchase agreement (the "Everett Purchase Agreement"). Pursuant to the Everett Purchase Agreement, the Company (through Mission Partners RE) completed its acquisition of 100% of the issued and outstanding membership interests of 29 Everett Street LLC, a Massachusetts limited liability company (the "Everett LLC"), which was solely held by Mr. Stevens and which owns certain real property that is currently leased to and used by NECC. The Company (i) paid Mr. Stevens cash in the amount of \$16,000,000, and (ii) issued Mr. Stevens a promissory note in the initial principal amount of \$2,000,000, which will bear interest at an annual rate of ten percent (10%) and matured on the six-month anniversary of January 28, 2022. On July 28, 2022, the parties amended the promissory note to provide for payment of half the principal on the initial maturity date, and the remaining principal and all accrued interest on September 12, 2022. The Merger and Purchase Agreement were recorded as one transaction (collectively, referred to as the "NECC Acquisitions"), as the entities were commonly owned by the same individual and the purchase of Everett LLC was contingent on the Merger with NECC.

The NECC Merger was accounted for as a business combination in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed in the NECC Merger. These values are subject to change as the Company completes its determination of the fair value of assets acquired and liabilities assumed. Upon acquisition of NECC and Everett LLC on January 28, 2022, the Company consolidated the operations of Everett LLC into NECC. As of the date of acquisition, the Company recognized NECC under the THC Cannabis segment as part of segment reporting.

The Company entered into the NECC Merger in order to acquire cannabis licenses, as well as property and equipment held by NECC to increase the Company's presence in Massachusetts and the northeastern United States. As part of the NECC, the Company incurred \$130 in restructuring costs, which were included in transaction and restructuring related expenses and expensed as incurred. As part of the NECC Merger, the Company incurred \$544 in transaction costs, which were included in transaction and restructuring related expenses and expensed as incurred.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

The following tables present the preliminary purchase price allocation for the NECC Merger:

Cash consideration	\$25,000
Seller note	2,000
Equity consideration - common stock	18,200
Total Purchase Price	\$45,200
	
Description	Fair value
Assets acquired:	
Cash	\$ 2
Inventory	213
Property, plant, and equipment	15,238
Intangible asset - licenses	18,000
Total assets acquired	\$ 33,453
Liabilities assumed:	
Accounts payable	800
Total liabilities assumed	\$ 800
Estimated fair value of net assets acquired	\$ 32,653
Estimated Goodwill	\$ 12,547

Goodwill and Intangible Assets

Goodwill is represented by the future potential for the generation of positive cash flows and future relationships associated with the Company's operations. While NECC had yet to generate revenues as of the date of the Merger, the Company identified that the inputs of the business were in place to begin generating revenue during fiscal year 2022. The Company adjusts provisional goodwill balance when new information is obtained regarding the valuation of acquired assets and liabilities during a one-year measurement period from the date of acquisition in accordance with ASC 805-10. The Company has determined that the goodwill recognized in the above acquisition is not deductible for tax purposes.

The intangible assets acquired by the Company consist of cannabis licenses for operations. Utilizing alike licenses as a benchmark, the Company determined that the licenses acquired are indefinite lived assets.

Island Merger Agreement

On March 30, 2022, the Company entered into an agreement and plan of merger (the "Island Merger Agreement") by and among the Company, Island Merger Sub, Island, and Navy (together the "Island Parties"). Pursuant to the terms and conditions of the Merger Agreement, Island Merger Sub merged with and into Island, with Island surviving the merger and continuing its corporate existence as a wholly owned subsidiary of the Company (the "Island Merger"). The Island Merger Agreement was to be effective as of April 25, 2022 (the "Effective Date").

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

On the Effective Date, the Island Parties consummated the Island Merger, pursuant to the terms and conditions of the Island Merger Agreement, as amended. However, due to administrative and technical issues at the California Office of the Secretary of State, the Island Parties did not receive the certificate of merger evidencing the closing of the Island Merger as of the Effective Date until April 25, 2022. At the Effective Date, pursuant to the terms and conditions of the Island Merger Agreement, as amended, the Company issued to certain shareholders and debtholders of Island an aggregate of: (i) 8,783,716 Class A Subordinated Voting Shares of the Company (the "SVS"); (ii) 6% 54-month, subordinated promissory notes (the "Island Merger Notes") in the aggregate principal amount of \$6,500,000; and (iii) warrants to purchase 2,999,975 SVS at a price of \$1.00 per SVS (the "Warrants", and together with the SVS and Island Merger Notes, the "Island Merger Consideration").

On April 22, 2022, the Parties entered into the first amendment to the Island Merger Agreement to replace the requirement that certain noteholders fund a letter of credit to Island of up to \$1,000,000. In lieu of funding a letter of credit, the noteholders agreed to pay the full \$1,000,000 in cash to Island on or prior to the closing of the transactions contemplated by the Island Merger Agreement.

The Island Merger was accounted for as a business combination in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed in the Island Merger. These values are subject to change as the Company completes its determination of the fair value of assets acquired and liabilities assumed. Upon acquisition of Island and Navy on April 25, 2022, the Company consolidated the operations of Navy into Island. As of the date of acquisition, the Company recognized Island under the THC Cannabis segment as part of segment reporting.

The Company entered into the Island Merger in order to add new high-quality products to the Company's growing brand portfolio, including diverse lines of pre-rolls, flower and infused products, as well as reduce production costs. As part of the Island Merger, the Company incurred \$1,288 in restructuring costs, which were included in transaction and restructuring related expenses and expensed as incurred. As part of the Island Merger, the Company incurred \$47 in transaction costs, which were included in transaction and restructuring related expenses and expensed as incurred.

The following tables present the preliminary purchase price allocation for the Island Merger:

Seller note	\$10,000
Equity consideration - common stock	6,245
Equity consideration - warrants	732
Total Purchase Price	\$16,977
	
<u>Description</u>	Fair value
Assets acquired:	
Cash	\$ 458
Accounts receivable	876
Inventory	3,072
Prepaid expenses and other current assets	424
Property and equipment, net	2,214
Operating lease - right of use asset	10,227
Intangible assets	11,300
Total assets acquired	\$ 28,571
Liabilities assumed:	
Accounts payable	\$ 1,356
Accrued expenses and other liabilities	2,566
Contract liabilities	3,535
Lease liabilities	10,227
Notes payable	245
Total liabilities assumed	\$ 17,929
Estimated fair value of net assets acquired	\$ 10,642
Estimated Goodwill	\$ 6,335

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Goodwill and Intangible Assets

Goodwill is represented by the future potential for the generation of positive cash flows and future relationships associated with the Company's operations. The Company adjusts provisional goodwill balance when new information is obtained regarding the valuation of acquired assets and liabilities during a one-year measurement period from the date of acquisition in accordance with ASC 805-10. The Company has determined that the goodwill recognized in the above acquisition is not deductible for tax purposes.

The intangible assets acquired by the Company consist of cannabis licenses, trade names and trademarks for operations. Utilizing alike licenses as a benchmark, the Company determined that the licenses acquired are indefinite lived assets and the trade names and trademarks have a life of ten years.

Unaudited Pro Forma Results

The following unaudited pro forma financial information presents the results of operations of the Company, NECC, and Island for the six months ended June 30, 2022 and 2021, as if the acquisitions had occurred as of the beginning of the first period presented instead of on January 28 and April 25, 2022, respectively. The pro forma information does not necessarily reflect the results of operations that would have occurred had the entities been a single company during those periods.

The unaudited pro forma financial information for the Company including NECC and Island for the three months ended June 30, 2022 is as follows:

	For the 1	For the For the Three Months Ended June 30,				
	20	22	2021			
	Reported Proforma		Reported	Proforma		
Revenues	\$28,439	\$28,706	\$27,121	\$28,922		
(Loss) income from operations	(4,099)	(5,444)	668	(936)		
Net loss	\$ (6,546)	\$ (8,932)	\$ (6,218)	\$ (8,115)		
Basic and diluted earning (loss) per share	\$ (0.01)	\$ (0.01)	\$ (0.01)	\$ (0.01)		

The unaudited pro forma financial information for the Company including NECC and Island for the six months ended June 30, 2022 is as follows:

	Fort	For the For the Six Months Ended June 30,				
	20	22	2021			
	Reported	Reported Proforma Re		Proforma		
Revenues	\$ 54,487	\$ 56,113	\$ 50,091	\$ 53,286		
(Loss) income from operations	(5,340)	(9,399)	1,021	(2,490)		
Net loss	\$(12,440)	\$(20,817)	\$(17,302)	\$(20,813)		
Basic and diluted earning (loss) per share	\$ (0.02)	\$ (0.03)	\$ (0.02)	\$ (0.04)		

Note 8: LEASES

The Company has operating leases for its facilities where the Company conducts its operations. These leases have remaining lease terms ranging from 1 year to 19.2 years.

All real estate leases are recorded on the balance sheet. Equipment and other non-real estate leases with an initial term of twelve months or less are not recorded on the balance sheet. Lease agreements for some locations provide for rent escalations and renewal options. Many leases include one or more options to renew the lease at the end of the initial term. The Company considered renewals in its right-of-use assets and operating lease liabilities. Certain real estate leases require payment for taxes, insurance and maintenance which are considered non-lease components. The Company accounts for real estate leases and the related fixed non-lease components together as a single component.

The Company determines if an arrangement is a lease at inception. The Company must consider whether the contract conveys the right to control the use of an identified asset. Certain arrangements require significant judgment to determine if an asset is specified in the contract and if the Company directs how and for what purpose the asset is used during the term of the contract.

There are no material residual guarantees associated with any of the Company's leases, and there are no significant restrictions or covenants included in the Company's lease agreements. Certain leases include variable payments related to common area maintenance and property taxes, which are billed by the landlord, as is customary with these types of charges for office space.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

The Company's lease agreements occasionally provide an implicit borrowing rate. When implicit borrowing rates are provided, the Company utilizes these implicit borrowing rates to calculate right-of-use assets and liabilities at the end of each reporting period. The Company may enter into leases that do not provide an implicit borrowing rate. When an implicit borrowing rate is not provided, the Company uses a benchmark approach to derive an appropriate imputed discount rate. The Company will benchmark itself against other companies of similar credit ratings and compare quality and derive an imputed rate, which was used in a portfolio approach to discount its lease liabilities.

For the three months ended June 30, 2022 and 2021 the Company recorded \$2,595 and \$2,400 in operating lease expense, respectively. For the six months ended six months ended June 30, 2022 and 2021 the Company recorded \$7,417 and \$4,868 in operating lease expense, respectively.

(a) The Company as a Lessee

The following table summarizes the Company's operating leases:

	Classification - Consolidated Balance Sheet June 30, 2022		December 31, 202	
Assets				
Operating lease assets	Operating Lease Assets	\$ 106,406	\$	100,519
Liabilities				
Current				
Operating	Current portion of operating lease liabilities	4,121		3,629
Noncurrent				
Operating	Operating lease liabilities	101,380		93,111
Total lease liabilities		\$ 105,501	\$	96,740

The components of lease expense are included in cost of goods sold, general and administrative expenses, and selling and marketing expenses, based on the underlying use of the right-of-use asset.

Maturities of lease liabilities for third-party operating leases as of June 30, 2022 were as follows:

	Ope	rating Leases
2022	\$	8,329
2023		16,987
2024		17,491
2025		17,633
2026		18,056
2027		18,076
2028 and Thereafter		234,359
Total undiscounted cash flows	\$	330,931
Less discounting		(225,430)
Total lease payments	\$	105,501

The Company has right-of-use assets and lease liabilities for leased real estate for dispensaries, cultivation and production facilities and office space. The incremental borrowing rate used for leases for 2022 was 10.25 - 18% and was 10.25 - 17% for 2021.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

(b) The Company as a Lessor:

The Company leases a building in Elma, Washington that is subleased by the Company to a third party. This sublease is classified as a finance lease with a long term lease receivable balance of \$6,541 and a short term lease receivable balance of \$3,405 as of June 30, 2022 compared to a long term lease receivable balance of \$6,748 and a short term lease receivable balance of \$3,630 as of December 31, 2021. This lease generated \$676 of the \$2,951 and \$570 of the \$2,669 in real estate income for the three months ended June 30, 2022 and 2021, respectively. This lease generated \$1,368 of the \$5,916 and \$1,361 of the \$5,559 in real estate income for the six months ended June 30, 2022 and 2021, respectively.

The Company owned buildings in Olympia, Washington that were leased to a third party. This lease was classified as a finance lease. On December 17, 2020, the Company sold the Olympia building and other assets as part of a sale and leaseback transaction and this lease was cancelled. The Company applied ASC 842 to a new sublease to the same third party and classified the new sublease as an operating lease. The lease receivable was sold to the purchaser of the assets as part of the sale and leaseback transaction. This lease generated \$2,275 of the \$2,951 and \$2,099 of the \$2,669 in real estate income for the three months ended June 30, 2022 and 2021, respectively. This lease generated \$4,548 of the \$5,916 and \$4,198 of the \$5,559 in real estate income for the six months ended June 30, 2022 and 2021, respectively.

The following table summarizes changes in the Company's lease receivables:

	June 30, 2022	Decen	nber 31, 2021
Balance, beginning of the year	\$ 10,378	\$	11,045
Interest	1,368		2,783
Lease payments received	(1,800)		(3,450)
Balance, end of the period	\$ 9,946	\$	10,378
Less current portion	(3,405)		(3,630)
Long-term lease receivables	\$ 6,541	\$	6,748

Future minimum lease payments receivable (principal and interest) on the leases are as follows:

	Operat	ing Leases
2022	\$	1,830
2023		1,575
2024		_
2025		_
2026		_
Thereafter		_
Total minimum lease payments		3,405
Effect of discounting		(431)
Present value of minimum lease payments		2,974
Present value of residual value of leased property		6,972
Total lease receivable		9,946
Current portion lease receivable		(3,405)
Long-term lease receivable	\$	6,541

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Note 9: NOTES PAYABLE AND CONVERTIBLE NOTES

The Company's notes payable and convertible notes are as follows:

	LI Lending, LLC	Co	ay 2020 nvertible Notes	F	22 Island Global Ioldings ated Party Notes	C	May 2020 onvertible otes (Swap)	ober 2021 nvertible Note	Other Loans	Total
Balance, December 31, 2020	\$ 45,362	\$	2,855	\$	_	\$	11,867	\$ _	\$ 6,931	\$ 67,015
Loans advanced, net	_		_				_	14,376	930	15,306
Loan payments	(4,671)		_		_		_	_	(1,079)	(5,750)
Converted to equity	_		(5,852)		_		(11,867)	_		(17,719)
Accrued interest	7,575		2,997		_		_	265	1,124	11,961
Balance, December 31, 2021	\$ 48,266	\$		\$	_	\$	_	\$ 14,641	\$ 7,906	\$ 70,813
Loans advanced, net	_		_		245		_	_	13,138	13,383
Loan payments	(2,526)		_		_		_	_	(130)	(2,656)
Converted to equity	_		_		_		_	_	(2,784)	(2,784)
Accrued interest	3,381		_		_		_	564	233	4,178
Balance, June 30, 2022	\$ 49,121	\$		\$	245	\$		\$ 15,205	\$18,363	\$ 82,934
Less current portion								 	(8,235)	(8,235)
Long-term portion	\$ 49,121	\$		\$	245	\$		\$ 15,205	\$10,128	\$ 74,699

Convertible Notes

On May 14, 2020, the Company issued \$5,827 in convertible notes to existing investors in the Company. The notes pay interest of 5% per annum and have a maturity date of February 28, 2022. The notes can be converted into SVS of the Company for \$0.25 per share at any time at the option of the holder. The Company was permitted to require mandatory conversion at any time that the Company's stock price remains above \$0.50 for 45 consecutive days. In 2021, the Company enacted the mandatory conversion feature and converted the May 2020 Convertible Note balance to subordinate voting shares.

As part of issuing the convertible notes, the investors were given the right to exchange stock in the Company into separate convertible notes (swap notes). In total 29,448,468 shares with a value of \$13,661 were exchanged for \$13,661 in convertible notes. These notes were effective May 28, 2020, have a maturity date of May 28, 2025, and can be converted into Class A Subordinate Voting Shares of the Company for \$0.46 per share at any time at the option of the holder. The notes pay no interest if the Company's annual revenue is greater than \$15,000, and 3% annually otherwise. The Company can require mandatory conversion at any time that the Company's stock price remains above \$0.92 for 45 consecutive days. In 2021, the Company exercised the mandatory conversion feature and converted the May 2020 Convertible Note (Swap) balance to subordinate voting shares.

On October 6, 2021, the Company entered into a convertible promissory note purchase agreement for \$15,000, less issuance costs of \$624, resulting in net proceeds of \$14,376. The notes pay interest of 6% per annum and have a maturity date of October 6, 2024. The notes can be converted into SVS of the Company for \$1.03 per share at any time at the option of the holder. As of June 30, 2022, no payments have been made for this loan.

LI Lending LLC

On May 10, 2019, the Company entered into a loan agreement with LI Lending LLC, a related party, for \$50,000. LI Lending LLC is related because an officer of the Company is a part-owner of LI Lending LLC. As of June 30, 2022, the Company had drawn \$45,000 on the loan in two amounts, an initial \$35,000 and a final \$10,000, both bearing a 10.25% and 12.25% interest rate, respectively. The outstanding balance as of June 30, 2022 is \$49,457, less debt discount of \$336, for a net balance of \$49,121. See Note 13 for further discussion of this related party transaction.

In April 2020, the loan was amended. In exchange for consent to allow the sale of the Pennsylvania and Maryland assets and the release of related collateral, the Company agreed to make prepayments of principal to LI Lending LLC in the amount of \$250 per month for an eight-month period beginning on May 1, 2020. The \$2,000 prepayment was applied to the initial \$35,000 amount, decreasing the balance to \$33,000. Additionally, the Company agreed to pay an increased interest rate of 12.25% on the final \$10,000 of the loan until such time as this amount has been paid down, with the initial \$33,000 amount continuing to be subject to the original 10.25% interest rate.

In December 2020, the loan was amended to allow for the release of collateral for the sale and leaseback transactions described in Note 8 above, which was entered into with Innovative Industrial Properties, Inc. ("IIPR"). The amendment increased both interest rates by 2.5% on the loan amounts but allowed the payments resulting from the incremental interest to be deferred until January 1, 2022. The Company elected to defer payment, and the additional 2.5% interest is accrued each month and added to the balance of the loan. The Company was required to make interest-only payments

monthly of 10.25% on the initial \$33,000 and 12.25% on the final \$10,000 of the loan until January 1, 2022 when the interest rates of 12.75% for the initial \$33,000 and 14.75% for the final \$10,000 took effect for the remaining term.

The loan matures on May 10, 2024. An exit fee of 20% of the principal balance will be due as principal is repaid. Accrued interest expense of \$3,381 includes a loan discount accretion expense of \$165 for the six months ended June 30, 2022. Accrued interest expense of \$1,490 includes a loan discount accretion expense of \$40 for the three months ended June 30, 2022. On January 1, 2022, the Company began making the required principal payments in addition to the interest payments for this loan. As of June 30, 2022, the Company has made \$2,526 in payments on this loan.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Other

Outstanding as of June 30, 2022 were other payables totaling \$18,363 which include notes issued as part of the acquisitions of Healthy Pharms, NECC, and Arkansas entities as follows:

Other

Subsidiary	Terms	June 30, 2022	December 3	1, 2021
Healthy Pharms Inc.	Unsecured convertible note, due November 18, 2021			
	at 12% per annum	\$ —	\$	2,784
Healthy Pharms Inc.	Unsecured promissory note at \$0.50 per share due			
	December 18, 2022 at 10% per annum (1)	3,377		3,213
Island Global	Promissory note due October 25, 2026 at 6% per			
	annum	10,128		_
NECC	Promissory note due September 12, 2022 at 10% per			
	annum	2,084		_
Om of Medicine, LLC	Promissory note due September 1, 2022 at 12% per			
	annum (3)	981		—
Arkansas Entities	Unsecured Promissory note due December 1, 2022,			
	monthly interest payments at 14% per annum	1,709		1,709
Equipment Loans	Secured by equipment, monthly payments beginning			
	in 2021 at 15% per annum	63		49
Other	Various	21		151
Total Notes Payable and				
Convertible Notes		\$ 18,363	\$	7,906

- (1) In November 2021, the unsecured promissory note was modified to be due and payable in full on or before December 18, 2022. The Company concluded the extension resulted in a debt modification under ASC 470.
- (2) In July 2022, the promissory note was modified, whereby 50% of the outstanding note payable was paid on July 28, 2022, and the remaining outstanding balance of the note was to be payable in full on or before September 12, 2022.
- (3) In April 2022, the Company entered into a seller note payable to pay the outstanding balance due resulting from the 2021 Om earnout in connection with prior period contingent considerations. The note bore 10% interest per annum and was due to be paid in full by July 1, 2022. At the time of the issuance of the note, the liability was current and was certain to be paid during 2022. In July 2022, the Company amended the note, whereby the Company paid \$345 of the remaining balance on the seller note and the term of the remaining balance of the seller note was extended to September 1, 2022, bearing interest at 12% per annum. If payment is not received in full by September 1, 2022, the remaining balance on the note will accrue interest at 20% per annum until payment is made in full. See Note 14 for further details on contingent considerations and the Om earnout.

Future minimum payments on the notes payable and convertible debt are as follows:

	Jun	e 30, 2022
2022	\$	8,235
2023		_
2024		64,326
2025		_
2026		12,874
Thereafter		
Total minimum payments		85,435
Effect of discounting		(2,501)
Present value of minimum payments		82,934
Less current portion		(8,235)
Long-term portion	\$	74,699

Construction Finance Liability

On January 28, 2022, a wholly owned subsidiary of the Company acquired property at 29 Everett in conjunction with the NECC Merger (see Note 7 for further details on the transaction). Concurrently, effective January 28, 2022, the Company sold a portion of the property it had acquired in the acquisition for \$16,000. In connection with the sale of the property at 29 Everett, the Company agreed to lease the location back for cultivation, effective on

January 28, 2022. The details of the lease included three purchase options that the Company can exercise, in which the Company has the ability to repurchase the property on either the second, fourth, or sixth anniversary of the lease agreement. The Company determined that the purchase and subsequent leasing of the land, building, and equipment at NECC was a sale of real estate, as the property and equipment sold as part of the building were interrelated with the building. Under *ASC 842 - Leases*, lease arrangements where assets are sold and leased back, whereby the transaction fails to meet the definition of a sale of an asset, does not meet the definition of a sale because control is never transferred to the buyer-lessor. The transaction did not meet the sale-and-lease back criteria under ASC 842, and the transaction was treated as a failed sale-leaseback financing arrangement. On January 28, 2022, the Company recorded a construction finance liability for the proceeds received from the sale to recognize a liability resulting from the failed sale-leaseback transaction.

The initial term of the agreement is 20 years, with two options to extend the term for five years each. The initial monthly rent payment is equal to \$140 for the first year of the agreement, with 3% annual increases over the life of the agreement. As of June 30, 2022, the total finance liability associated with this transaction is \$16,000. The total interest expense incurred during the six months ended June 30, 2022 was \$700.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Note 10: SHARE CAPITAL AND EQUITY

The Company has authorized an unlimited number of Class A Subordinate Voting Shares ("SVS") and Class C Multiple Voting Shares ("MVS"), all with no par value. In December 2020, the shareholders of the Company passed a resolution to permit the Company to convert all Class B Subordinate Voting Shares ("PVS") shares into Class A shares and cancel the Class B PVS equity class, which occurred in 2020.

All share classes are included within share capital in the consolidated statements of stockholders' equity on an as- converted basis. Each share class is entitled to notice of and to attend at any meeting of the shareholders, except a meeting of which only holders of another particular class of shares will have the right to vote. All share classes are entitled to receive dividends, as and when declared by the Company, on an as-converted basis, and no dividends will be declared by the Company on any individual class unless the Company simultaneously declares or pays dividends on all share classes. No subdivision or consolidation of any share class shall be made without simultaneously subdividing or consolidating all share classes in the same manner

Voting shares activity for the periods presented is summarized as follows:

	Class A Subordinate Voting Shares	Class C Multiple Voting Shares	Total
Balance, December 31, 2020	537,575,044	1,276,208	538,851,252
Share capital issuances	55,330,352		55,330,352
Balance, December 31, 2021	592,905,396	1,276,208	594,181,604
Share capital issuances	43,731,290		43,731,290
Balance, June 30, 2022	636,636,686	1,276,208	637,912,894

Class A Subordinate Voting Shares

Holders of Class A Subordinate Voting Shares are entitled to one vote in respect of each SVS.

Class C Multiple Voting Shares

Holders of Class C Multiple Voting Shares are entitled to 800 votes in respect of each MVS. One MVS can convert to one SVS but are not convertible until the later of the date that (i) the aggregate number of PVS and MVS held by the Initial Holders (being the MVS holders on their initial issuance) are reduced to a number which is less than 50% of the aggregate number of PVS and MVS held by the Initial Holders on the date of completion of the Business Combination with Cannex, and (ii) 3 years following the date of the business combination with Cannex.

Series	Shares outstanding as of June 30, 2022	As converted to SVS Shares
Class A - Subordinate Voting Shares	636,636,686	636,636,686
Class C - Multiple Voting Shares	1,276,208	1,276,208
	637,912,894	637,912,894

On November 23, 2020, the Company closed a brokered private placement and issued 24,644,500 Units at a price of C\$0.70 per Unit. Each Unit is comprised of one subordinate voting share of the Company and one-half of a subordinate voting share purchase warrant. Each whole warrant entitles the holder to purchase one subordinate voting share for a period of two years from the date of issuance at an exercise price of C\$0.90 per subordinate voting share. Net proceeds from this transaction were \$11,557 net of share issuance costs of \$690.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Because of the Canadian dollar denominated exercise price, these warrants do not qualify to be classified within equity and are therefore classified as derivative liabilities at fair value with changes being reported through the statement of operations. On November 23, 2020, the warrants were valued using the Black Scholes option pricing model at \$4,229 using the following assumptions: Share Price: C\$0.94; Exercise Price: C\$0.90; Expected Life: 2 years; Annualized Volatility: 87.73%; Dividend yield: 0.00%; Discount Rate: 0.16%; C\$ Exchange Rate:1.31.

On June 30, 2022, the warrants were revalued using the Black Scholes option pricing model, using the following assumptions: Share Price: C\$0.71; Expected Life: 0.4 years; Annualized Volatility: 61.40%; Dividend yield: 0.00%; Discount Rate: 2.51%; C\$ Exchange Rate: 1.29. The decrease in the value of the derivative liability of \$3,074 is reflected in the statement of operations as a \$3,074 gain on the change in fair value of the derivative liability.

Note 11: WARRANTS

As of June 30, 2022, there were share purchase warrants outstanding to purchase up to 29,103,553 SVS shares:

Series	Number of warrants	t-average ise price
Balance, December 31, 2021	26,192,237	\$ 0.75
Issued	2,999,975	1.00
Exercised	(88,659)	0.56
Balance, June 30, 2022	29,103,553	\$ 0.75

As of June 30, 2022, the Company has the following warrants outstanding:

Warrants Outstanding		Exercise Price		Expiry Date
	10,403,150	C\$	0.90*	November 23, 2022
	209,426	C\$	0.70*	November 23, 2022
	12,135,922	\$	0.82*	December 17, 2022
	2,230,080	\$	0.67*	January 29, 2023
	2,999,975	\$	1.00	April 13, 2024
	625,000	C\$	0.80*	October 6, 2024
	500,000	C\$	0.80*	October 6, 2025
	29,103,553			

^{*} Represents warrants that are exercisable as of June 30, 2022.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Note 12: SHARE-BASED COMPENSATION

The Company adopted two equity incentive plans where the Company may grant Class A stock options. Under the terms of the plans, the maximum number of stock options which may be granted are a total of 10% of the number of shares outstanding assuming conversion of all shares to SVS. The exercise price for stock options issued under the plans will be set by the compensation committee of the board of directors but will not be less than 100% of the fair market value of the Company's shares on the grant date. Stock options have a maximum term of 10 years from the date of grant. Stock options vest at the discretion of the Board.

As of June 30, 2022, the Company had the following options outstanding and exercisable on an as-converted basis:

Grant Date	Strike Price in CAD\$	Outstanding Options	Exercisable Options	Life Remaining (years)
July 31, 2019	0.10	6,245,840	6,245,840	2.22
July 31, 2019	1.00	7,783,332	7,783,332	0.45
July 31, 2019	1.00	1,166,667	1,166,667	1.27
July 31, 2019	1.50	508,333	508,333	1.95
July 31, 2019	1.50	800,000	800,000	1.96
August 22, 2019	0.80	5,237,720	4,459,942	2.15
August 22, 2019	1.00	6,150,000	5,522,222	2.15
November 1, 2019	0.80	1,200,000	1,000,000	2.34
February 3, 2020	0.80	348,333	148,333	2.60
June 8, 2020	0.80	25,000	12,500	2.94
July 31, 2020	0.80	1,200,000	1,150,000	3.09
September 15, 2020	0.86	7,315,860	7,315,860	3.21
October 2, 2020	0.77	3,000,000	3,000,000	3.26
November 24, 2020	0.94	1,675,000	1,675,000	3.41
December 2, 2020	1.11	2,900,000	2,900,000	3.43
December 21, 2020	1.06	1,200,000	600,000	3.48
March 18, 2021	1.63	6,375,000	4,158,333	3.72
April 2, 2021	1.36	166,667	100,000	3.76
April 21, 2021	1.58	175,000	116,667	3.81
June 23, 2021	1.56	250,000	216,667	3.98
November 11, 2021	1.33	25,000	6,250	4.37
January 25, 2022	0.89	975,000	209,896	4.58
February 1, 2022	0.84	100,000	20,556	4.59
February 17, 2022	0.85	100,000	14,167	4.64
March 1, 2022	1.09	200,000	33,333	4.67
April 27, 2022	0.90	1,200,000	71,111	4.83
June 17, 2022	0.77	3,735,000	723,661	4.97
		60,057,752	49,958,670	2.72

Stock option activity is summarized as follows:

	Number of Options	Weighted Average Price CAD\$	Weighted Average Years
Balance December 31, 2020	50,427,065	0.84	3.72
Granted	7,900,000	1.62	5.00
Exercised	(2,737,326)	1.04	_
Forfeited/ Expired	(1,306,987)	0.43	_
Balance December 31, 2021	54,282,752	0.94	2.97
Granted	6,435,000	0.83	5.00
Exercised	(51,975)	0.80	_
Forfeited/ Expired	(608,025)	1.62	
Balance June 30, 2022	60,057,752	0.92	2.72

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

During the six months ended June 30, 2022 and 2021, the Company recognized share-based compensation of \$1,428 and \$5,375. During the three months ended June 30, 2022 and 2021, the Company recognized share-based compensation of \$390 and \$2,979, respectively.

In determining the amount of equity-based compensation during the year, the Company used the Black-Scholes option pricing model to establish fair value of options granted during the year with the following key assumptions:

	2022	2021
Risk-Free Interest Rate	2.42%	0.87% to 0.92%
Expected Life (years)	5.00	5.00
Expected Annualized Volatility	71.30%	86.2% to 93.53%
Forfeiture rate	— %	— %
Expected Dividend Yield	— %	— %

Note 13: RELATED PARTIES

Related party transactions

LI Lending LLC

Linchpin Investors LLC ("Linchpin"), a subsidiary of the Company, and LI Lending LLC ("LI Lending") entered into a Construction Loan Agreement dated May 10, 2019, as amended, whereby Linchpin received an up-to \$45,000 loan from LI Lending of which \$48,300 was outstanding as of December 31, 2021. Mr. Gontmakher, the CEO of the Company, and Roman Tkachenko, a director of the Company, each hold a 14.28% ownership interest in LI Lending. The loan matures in May 2024 and bears interest at 10.25%, payable monthly in cash. Upon maturity, an exit fee of \$9 million is payable, for a total payable at maturity of \$54 million. \$49,457 of the loan advanced includes the notes payable and accrued interest less debt discount of \$336 that was outstanding as of June 30, 2022. Of the \$49,121 outstanding at June 30, 2022, \$3,381 represents interest accrued through June 30, 2022. See Note 9 for details on the outstanding note payable.

Pure Ratios

Leonid Gontmakher, Chief Executive Officer of the Company, holds an interest in an entity related to iWolf Management, LLC, an online marketing company serving the online CBD market which provided online marketing services during 2020 and 2019 for the Company's Pure Ratios division. Pure Ratios paid \$313 for the three and six months ended June 30, 2021 to this vendor for management fees, pass through marketing costs and customer service. Pure Ratios did not make any such payments during the six months ended June 30, 2022.

MP Illinois

The Company maintains a contractual relationship with entities that are wholly owned by MP Illinois, a single-member LLC owned by Mr. Joshua N. Rosen, a former officer and director of the Company. The Company holds a nominee agreement whereby the Company receives a 100% beneficial (but not legal) interest IL Grown Medicine, LLC, the holder of a cultivation license in Illinois.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Note 14: CONTINGENCIES

(a) Cannabis Industry

Cannabis is still considered a Schedule I substance under the Controlled Substance Act. As such, there is an inherent risk related to the federal government's position on cannabis; additionally, the risk exists, due to the Company's business in cannabis, that third party service providers could suspend or withdraw services and as well as the risk that regulatory bodies could impose certain restrictions on the issuer's ability to operate in the U.S.; however, the Company has deemed it not reasonable to estimate a potential liability related to the possible enforcement of laws against the medical cannabis industry.

(b) Contingent consideration payable

As part of the acquisition of Om of Medicine, LLC and Cannex's prior acquisition of Pure Ratios, the Company is subject to contingent consideration payable to the sellers. The fair value of the contingent consideration, which is based on specific revenue levels achieved over a 2-3-year period, is as follows:

	Om of Medicine
Balance, December 31, 2021	\$ 2,393
Changes in fair value	(2,393)
Balance, June 30, 2022	_
Less: current portion	
Long-term portion	\$ —

The contingent consideration payable is measured at fair value based on unobservable inputs and is considered a Level 3 financial instrument. The determination of the fair value of these liabilities is primarily driven by the Company's expectations of the respective subsidiaries achieving certain milestones. The expected milestones were assigned probabilities and the expected related cash flows were discounted to derive the fair value of the contingent consideration. The Company reached expected milestones during the year ended December 31, 2021, which resulted in a contingent consideration payment of \$1,373 that was due to be paid by the Company in 2022. The Company paid \$412 of the outstanding balance in April 2022. As discussed in Note 9, in April 2022, the Company entered into a seller note to pay the outstanding balance of the liability. The term of the note expires in six months and accrues interest at 10% per annum. See Note 9 for the outstanding balance of the note payable as of June 30, 2022.

The Company had an outstanding balance of contingent consideration of \$2,393 for the period ended December 31, 2021, which included the liability noted above. However, the Company performed analyses and determined that it does not anticipate the subsidiaries to reach the required milestones, as detailed below, for the year ended December 31, 2022. As a result, the Company estimated the contingent consideration to be \$nil as of June 30, 2022.

OM of Medicine: The contingent consideration payable is determined as the amount in excess of gross sales of \$3,400 (for fiscal 2021) and \$3,500 (2022) to a maximum payable of \$6,900.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

(c) Legal Matters

From time to time, the Company may be involved in certain disputes arising in the ordinary course of business. Such disputes, taken in the aggregate, are not expected to have a material adverse effect on the Company. There are also no proceedings in which any of the Company's directors, officers, or affiliates is an adverse party or has a material interest adverse to the Company's interest.

On May 15, 2017, the Company's wholly-owned subsidiary, 4Front Advisors, LLC, entered into an Application, Training, and Consulting Agreement with 5Seat Investment, LLC and Kanna. A dispute arose about amounts owed to the subsidiary under the agreement, and on May 17, 2022, the parties agreed to settle the matter for payment of \$600 to the Company's subsidiary.

On January 26, 2022, Savills, Inc. sued the Company in the U.S. District Court for the Southern District of New York. That lawsuit alleged that the Company had breached an alleged agreement with Savills under which the Company was allegedly required to pay Savills a percentage of savings realized under certain incentive programs offered in some jurisdictions, which Savills would assist the Company in obtaining. Savills claimed damages of approximately \$19,000 in connection with its claim that it obtained benefits for the Company allegedly valued at over \$129,000. The Company denied these allegations, denied the Company had obtained such benefits, disputed Savills' characterization of the facts, and denied liability. The Company filed a counterclaim against Savills alleging breach of contract by Savills. On August 3, 2022, the parties reached a confidential settlement in principle and agreed to dismissal of all claims. In accordance with the order of dismissal, if no application to restore the litigation is submitted by September 6, 2022, the case will be dismissed without prejudice.

Note 15: FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT

ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. The Company follows this authoritative guidance for fair value measurements, which defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles in the United States of America, and expands disclosures about fair value measurements. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:

Level 1	Quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2	Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and

Level 3 Inputs for the asset or liability that are not based on observable market data (unobservable inputs).

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the periods ended June 30, 2022 and December 31, 2021. The fair value of the Company's cash, accounts receivable, other receivables, accounts payable and accrued expenses approximates carrying value due to their short-term nature. The Company's notes receivable, lease receivables, contingent consideration payable, derivative liabilities, convertible notes payable, construction finance liability and notes payable approximate fair value due to the instruments bearing market rates of interest or their short term nature. As the interest rates utilized to calculate these instruments approximates market value interest rates, the carrying amounts of the instruments approximate fair value, which are primarily based on Level 1 inputs. The fair value of stock options granted were estimated based on a Black-Scholes model during the periods ended June 30, 2022 and December 31, 2021. The estimated fair value of the derivative liabilities, which represent embedded put included in the convertible notes payable, represent Level 3 measurements.

The following table details the fair value measurements within the fair value hierarchy of the Company's financial instruments, which includes the Level 3 liabilities:

		Fair value at June 30, 2			
	<u>Total</u>	Level 1	Level 2	Level 3	
Liabilities:					
Derivative liability	\$428	<u>\$ —</u>	\$ —	\$ 428	
Total liabilities	\$428	\$ —	\$ —	\$ 428	
	Fair	value at Dece	mber 31, 2021	1	
	Total	Level 1	Level 2	Level 3	
Liabilities:					
Derivative liability	\$3,502	<u>\$</u>	<u>\$</u>	\$3,502	
Total liabilities	\$3,502	\$ —	\$ —	\$3,502	

The table below provides a summary of the changes in fair value of the derivative liabilities measured on a recurring basis using significant unobservable inputs (Level 3):

	For the Six Months Ended June 3 2022 2021		
Derivative liability:			
Balance, beginning of period	\$ 3,502	\$	5,807
(Gain) loss on fair value of derivative liability	(3,074)		2,843
Change in fair value of derivative liability upon exercise of warrants	_		(1,427)
Balance, end of period	\$ 428	\$	7,223

There were no transfers between fair value levels for the six months ended June 30, 2022 and the year ending December 31, 2021.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

(a) Financial Risk Management

The Company is exposed in varying degrees to a variety of financial instruments related risks. The Board mitigates these risks by assessing, monitoring and approving the Company's risk management processes.

(b) Credit Risk

Credit risk is the risk of loss associated with a counterparty's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to cash, lease receivables, other receivables, and notes receivable. The Company's maximum credit risk exposure is equivalent to the carrying value of these instruments.

The risk exposure is limited to the carrying amounts at the statement of financial position date. The risk to cash deposits is mitigated by holding these instruments with regulated financial institutions. Lease receivables, notes receivables and other receivables credit risk arises from the possibility that principal and interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationships.

The Company maintains cash with federally insured financial institutions. As of December 31, 2021, the Company exceeded federally insured limits by approximately \$10,866. The Company did not exceed any federally insured limits at any of its financial institutions for the six months ended June 30, 2022. The Company has historically not experienced any losses in such accounts. As of June 30, 2022, the Company held approximately \$9 in cash in a Canadian account that is denominated in C\$.

As of June 30, 2022 and December 31, 2021, the maximum credit exposure related to the carrying amounts of accounts receivable, other receivable, notes receivable and lease receivables was \$15,823 and \$12,722, respectively.

(c) Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company manages liquidity risk through the management of its capital structure. The Company's approach to managing liquidity is to raise sufficient capital to settle obligations and liabilities when due.

The Company has the following obligations as of June 30, 2022, which are expected to be payable in the following respective periods:

	Less than			Greater than 5	
	1 year	1 to 3 years	3 to 5 years	years	Total
Accounts payable and accrued liabilities	\$19,422	\$ 1,200	\$ —	\$ —	\$ 20,622
Convertible notes, notes payable and accrued interest	8,235	74,699	_		82,934
Contingent consideration payable	_	_	_	_	
Construction finance liability		16,000			16,000
Total	\$27,657	\$ 91,899	\$ —	\$ —	\$119,556

(d) Interest Rate Risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

(e) Foreign Exchange Risk

The Company is exposed to exchange rate fluctuations between United States and Canadian dollars. The Company's share price is denominated in Canadian dollars. If the Canadian dollar declines against the United States dollar, the United States dollar amounts available to fund the Company through the exercise of stock options or warrants will be less. The Company also has bank accounts with balances of \$9 in Canadian dollars. The value of these bank balances if converted to U.S. dollars will fluctuate. While the Company maintains a head office in Canada where it incurs expenses primarily denominated in Canadian dollars, such expenses are a small portion of overall expenses incurred by the Company. The Company does not have a practice of trading derivatives and does not engage in "natural hedging" for funds held in Canada.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

(f) Other Price Risk

Price risk is the risk of variability in fair value due to movements in equity or market prices. The Company is subject to risk of prices to its products due to competitive or regulatory pressures.

Note 16: SEGMENT INFORMATION

Reportable Segments

Operating segments are components of the Company that combine similar business activities, with activities grouped to facilitate the evaluation of business units and allocation of resources by the Company's board of directors and management. As of June 30, 2022, the Company had two reportable segments:

- THC Cannabis Production and cultivation of THC cannabis, manufacturing and distribution of cannabis products to own dispensaries and third-party retail customers, ancillary services supporting wholesale operations, and retail sales direct to end consumers; and
- CBD Wellness Pure Ratios which encompasses the production and sale of CBD products to third-party customers.

The results of each segment are regularly reviewed by the Company's Chief Executive Officer, who is the Company's chief operating decision maker, to assess the performance of the segment and make decisions regarding the allocation of resources. The Company's chief operating decision maker uses revenue and net loss as measure of segment performance. There are no intersegment sales or transfers. All revenues are derived from customers domiciled in the United States and all assets are located in the United States.

The below table presents revenues, depreciation and amortization, and net (income) loss by type for the three and six months ended June 30, 2022 and 2021, as well as assets by type as of June 30, 2022 and December 31, 2021:

	Th	Three Months Ended June 30, 2022 2021			Six Months Ended 2022			ed June 30, 2021	
Net Revenues									
THC Cannabis	\$	28,195	\$	26,396	\$ 5	3,978	\$	48,544	
CBD Wellness		244		725		509		1,547	
Corporate									
Total Net Revenues		28,439		27,121	5.	4,487		50,091	
Depreciation and Amortization									
THC Cannabis		1,123		833		1,970		1,589	
CBD Wellness		—				—		16	
Corporate				28				30	
Total Depreciation and Amortization		1,123		861		1,970		1,635	
Net (Income) Loss									
THC Cannabis		3,846		1,003		4,102		3,841	
CBD Wellness		(104)		817		(119)		820	
Corporate		2,809		4,403		8,467		12,651	
Total Net Loss	\$	6,551	\$	6,223	\$ 1	2,450	\$	17,312	

Assets	June 30, 2022	December 31, 2021		
THC Cannabis	\$ 318,795	\$	238,933	
CBD Wellness	781		805	
Corporate	881		15,801	
Total Assets	\$ 320,457	\$	255,539	

Goodwill assigned to the THC Cannabis segment as of June 30, 2022 and December 31, 2021 was \$42,037 and \$23,155, respectively. Intangible assets, net assigned to the THC Cannabis segment as of June 30, 2022 and December 31, 2021 were \$54,239 and \$26,246, respectively.

The Company did not have any Goodwill or intangible assets assigned to the CBD Wellness segment as of June 30, 2022 and December 31, 2021.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2022 and 2021 (unaudited)

(Amounts expressed in thousands of U.S. dollars except for share and per share data)

Note 17: SUPPLEMENTARY CASH FLOW INFORMATION

Changes in non-cash working capital:

	Jun	e 30, 2022	June 30, 2021		
Changes in operating assets and liabilities					
Accounts receivable and other receivables	\$	(2,766)	\$	(815)	
Inventory		(5,302)		(4,563)	
Prepaid expenses		(318)		50	
Deposits		222		(70)	
Accounts payable and accrued liabilities		4,939		65	
Taxes payable		5,683		5,163	
	\$	2,458	\$	(170)	

Supplemental disclosure of non-cash investing and financing activities:

	June 30, 2022		June 30, 2021	
Exchange of convertible debt to equity	\$	3,122	\$	17,719
Change in right-of-use assets and lease liabilities	\$	8	\$	153
Issuance of equity to pay contingent consideration	\$		\$	883
Issuance of debt to pay contingent consideration	\$	_	\$	485
Equity portion of warrants recorded through derivative liability	\$	_	\$	1,427
Issuance of equity for NECC pursuant to acquisition	\$	18,200	\$	_
Property, plant, and equipment acquired through NECC acquisition	\$	15,238	\$	_
Issuance of notes payable through NECC acquisition	\$	2,000	\$	_
Inventory acquired through NECC acquisition	\$	213	\$	_
Issuance of equity for Island pursuant to acquisition	\$	6,245	\$	_
Issuance of warrants for Island pursuant to acquisition	\$	732	\$	_
Property and equipment acquired through Island acquisition	\$	2,214	\$	
ROU asset and lease liability acquired through Island acquisition	\$	10,227	\$	_
Note payable acquired through Island acquisition	\$	245	\$	
Issuance of notes payable through Island acquisition	\$	10,000	\$	_
Inventory acquired through Island acquisition	\$	3,072	\$	
Issuance of debt to acquire property and equipment	\$	14	\$	445
Inventory acquired through issuance of note payable	\$	163	\$	
Cancellation of ROU asset and lease liability	\$	2,020	\$	
Note payable issued to satisfy accrued expenses	\$	961	\$	

- Cash paid for interest for the six months ended June 30, 2022 and 2021 was \$3,174 and \$1,662, respectively.
- Cash paid for income taxes for the six months ended June 30, 2022 and 2021 was \$2,100 and \$224, respectively.

Note 18: INCOME TAXES

The following table summarizes the Company's income tax expense:

	_Fo	For the Three Months Ended June			For the Six Months Ended June 30,			
		2022		2021		2022		2021
Net loss before income taxes	\$	(3,504)	\$	(2,867)	\$	(5,960)	\$	(11,298)
Income tax expense		(3,042)		(3,351)		(6,480)		(6,004)

The Company has computed its provision for income taxes under the discrete method which treats the year-to-date period as if it were the annual period and determines the income tax expense or benefit on that basis. The discrete method is applied when application of the estimated annual effective tax rate is impractical because it is not possible to reliably estimate the annual effective tax rate. The Company believes the use of this discrete method is

more appropriate than the annual effective tax rate method due to the early growth stage of the business. At this time, there is a high degree of uncertainty in estimating the Company's annual pre-tax income and significant non-deductible expenses so the Company cannot reliably estimate the annual effective tax rate.

Internal Revenue Code ("IRC") Section 280E denies, at the U.S. federal level, deductions, and credits attributable to a trade or business trafficking in controlled substances. Because the Company is subject to IRC Section 280E, the Company has computed its U.S. tax based on gross receipts less cost of goods sold. The tax provisions for the six months ended June 30, 2022 and 2021, have been prepared based on the assumption that cost of goods sold is a valid expense for income tax purposes.

The federal statute of limitation remains open for the 2018 tax year to the present. The state income tax returns generally remain open for the 2017 tax year through the present. Net operating losses arising prior to these years are also open to examination if and when utilized.

Note 19: SUBSEQUENT EVENTS

On July 13, 2022, Kathi Lentzsch resigned from her role as Chair of the Board, while remaining a Director and Chair of the Compensation Committee, and Mr. Robert Hunt was appointed Chair of the Board.